| Marc Feldmann, M.D., Ph.D., Professor and Director, Kennedy Institute of Rheumatology, Imperial College, London
A leader in the discovery and development of targeted drugs that affect immune-related disorders, Dr. Feldmann is a co-recipient of the Lasker Award for the development of Remicade® (Centocor) for rheumatoid arthritis and Crohn’s disease.
Jordan U. Gutterman, M.D., Professor of Medicine, Chief of the Section of Cellular and Molecular Growth Regulation, University of Texas MD Anderson Cancer Cente
Dr. Gutterman’s early clinical investigations of interferon-alpha led to the first major breakthrough drug of the nascent biotechnology industry. He has been a consultant to leading pharmaceutical and biotechnology companies, and for the past decade has served as chairman of the Lasker Awards.
Mark Pegram, M.D., Professor of Medical Hematology and Oncology, Director of the Women Cancers Program Area, University of California Los Angeles
Dr. Pegram is a principal investigator for the UCLA arm of a new experimental treatment for ovarian cancer. He was a co-investigator on landmark research that led to the development of Herceptin, the first gene-based breast cancer drug that has opened a new era in treating women with an aggressive form of the disease.
Dennis Slamon, M.D., Ph.D., Chief of Hematology and Oncology, University of California Los Angeles School of Medicine
Dr. Slamon is a world-renowned leader in the discovery and clinical development of targeted cancer therapeutics and the recipient of the Landon Prize from the American Association for Cancer Research for the development of Herceptin.
David F. Stern, Ph.D., Professor of Pathology, Yale University School of Medicine; co-leader, Signal Transduction Research Program, and Associate Director of Research, Yale Comprehensive Cancer Center
Dr. Stern established many of the principles underlying development of the HER2 antibody drug Herceptin. His laboratory investigates the biology of EGF receptor, HER2, and other receptor kinases in cancer; DNA checkpoint signal transduction; and optimal strategies for personalizing use of molecularly targeted cancer therapies.
Axel Ullrich, Ph.D., Professor and Director, Department of Molecular Biology, Max Planck Institute of Biochemistry, Martinsried (Germany)
Dr. Ullrich’s interests in translating basic science into medical applications have led to the development of Humulin® (Eli Lilly and Co., human insulin), the first therapeutic agent to be developed through rDNA technology; Herceptin; and more recently, Sutent (Pfizer), a multi-targeted drug for the treatment of gastrointestinal stromal tumors (GIST) and renal cell carcinoma. A leader in international biotechnology development, Dr. Ullrich is a founder of SUGEN Inc. (USA), Axxima Pharmaceuticals AG (Germany) and U3 Pharma AG (Germany).
Ronald Wetzel, Ph.D., Professor, Department of Structural Biology and Pittsburgh Institute for Neurodegenerative Disease, University of Pittsburgh School of Medicine
Dr. Wetzel began his career in the early years of Genentech, where, working on the insulin, interferon, and immunoglobulin projects, he developed a keen interest in protein folding and misfolding. For the past 15 years he has been applying his expertise in protein chemistry and biophysics to studies of the role of protein misfolding and amyloid formation in neurodegenerative diseases like Alzheimer’s and Huntington’s diseases.
| |
